Mayo Clinic, headquartered in Rochester, Minnesota, has forged a multiyear collaboration with Oxford Nanopore, a United Kingdom-based firm, to delve into the genetic predispositions to cancer.
Leveraging Oxford Nanopore's cutting-edge nanopore-based molecular sensing technology, Mayo Clinic researchers can now pioneer novel clinical tests for sequencing a patient's DNA while concurrently analysing methylation, a crucial biochemical process governing gene expression, in real time.
This transformative advancement eliminates the need for separate, time-consuming, and costly procedures to examine methylation. Consequently, healthcare practitioners can gain a more comprehensive understanding of a patient's cancer genome with unprecedented immediacy.
Dr. Bobbi Pritt, serving as the interim chair of Mayo Clinic's Department of Laboratory Medicine and Pathology, emphasised that this partnership marks a significant step towards advancing patient care.
Click here to read the original news story.